Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MVES WEDMAN,this is looking good,with all the things $MVES has going on, revenues will start to show and we will fly,lot of big holders here who are holding tight and wont be selling for a long time
$MVES looking good today,a little volume could move us fast
$SPRV Lanemyers I agree,wont take much to set this off,less than a 100 mil on the ones,they could get wiped out fast
$SPRV picking up followers on twitter,should pick up fast once they start tweeting
$MVES, should be getting an update on how the film festival went
$MVES hopefully we get some news from the movie festival this week,think it ends today
I dont think sonny has bk in his mind at all.We only got like 5 million shares out.If we need money we can raise it through shares some how I would think.I think were just stalling entill a BO is all worked out and signed,They may be waiting on some approval or some thing.Plus zimmer just got a new CEO,so they may be wanting it not to look like he rushed into a deal,even though the deal may have been all worked out before he got there.But companys like new ceos to come in with a bang and look good for share holders so he will get all the credit,But I do think BO is in progress, JMO
I think alot of us here wish the same thing,but our ignore buttons are full,things are looking good here cherry,great time to be in $INMG load the dips
$MVES CAYO, nice move,your account is going to be fun to watch once we start moving,with the low share structure and low float we will move fast,news should be coming soon on some updates like the movie RAINBOW,should be a big money maker for $MVES.with mves being so quiet wouldnt be surprised if there some deal making going on right now,gets your drinks and popcorn ready cayo its going to be fun
$MVES,CAYO these stocks all move in there own time,when there ready they go,look at dnax the last 2 days,today they traded 1.8 billion shares so far,its been dead for a couple of years and sprv has been dead for a few years now its taking off with good volume.just got to load em while its slow and enjoy the ride.Ive been looking to buy another farm hopefully will find one this spring and $MVES will be paying for it.$MVES is a great company just getting started,all of a sudden it will take off without notice,and we will make alot of money glmf
$SPRV looking good just got to chew through the one tick flippers,by friday we should be looking real good
$MVES, This could be a vary big year for $MVES,market watchers give a 40% chance that apple could buy out netflix.With all the money coming home with the new tax laws,apple says its going to bring home about $200 billion,I think we could see alot of M and A activity.With all the content that $MVES has we are sitting pretty for a BO.Going to be a interesting year.I got a good chunk of shares and wont be selling any entill some thing big happens GLTA
$SPRV lets hope for some big news this week and watch the stock fly,could be a fun ride $SPRV
$SPRV floridaboy,something is brewing,looking for some big news to come out
with a new website hopefully were getting ready for some big news,good to see volume picking up
MedTech
Cash-rich Zimmer Biomet will have $4.7B to spend on M&A over next few years: Analyst
Mar 18, 2016 9:19am
Share
Facebook
Twitter
LinkedIn
Email
Print
Zimmer's Pulsavac Plus device to clear debris during orthopedic surgery--Courtesy of Zimmer
Thanks to Zimmer's $14 billion acquisition of Biomet, now Zimmer Biomet ($ZBH) will have $4.7 billion in cash at its disposal over the next few years and will be free to spend the proceeds on U.S. M&A activity, share buybacks and debt reduction, says Jefferies equity analyst Raj Denhoy in an analyst note.
Of the three value-creation activities, additional share repurchases beyond those already planned are the company's lowest priority, according to the analyst, while paying back debt early generates a limited return given its 3% cost. Instead, more M&A activity could be on the way for the orthopedics specialist, as it seeks accelerated top-line growth.
In January, Zimmer projected constant-currency revenue growth of 1.5% to 2.5% in 2016. Denhoy believes that the dis-synergies from the Biomet deal are behind the company, and said it should return to "market growth" by the end of the year, but that's only 3% to 4%, a reflection of the mature markets for hip and knee implants.
"The prospect of accelerating revenue growth is perhaps more intriguing, as Zimmer has historically traded at a discount to its medtech peers--partially we believe because of the perception that the company was satisfied with remaining in the lower growth markets of hips and knees. An M&A driven expansion into other areas, or increasing its size in the existing SET (Surgical, Sports Medicine, Extremities and Trauma) or Spine segments, could cause a recalibration of that view," Denhoy wrote.
Despite the growth concerns, the analyst believes the "windfall" from the company's $14 billion acquisition of Biomet is not being appreciated. The combined company will generate a total of $8.7 billion in free cash flow by 2020, Denhoy said.
"Ordinarily not all of that cash would be available in the U.S., as Zimmer generates about 45% of its cash outside the U.S., but through the Biomet acquisition the company structured intercompany loans with its foreign subsidiaries. This structure will allow it to repatriate close to $4bn of overseas cash with minimal, if any, tax burden," he wrote.
In addition, the company mentioned in an SEC filing in February that it has booked a $1.5 billion tax liability to repatriate $4.4 billion to the U.S. in future periods, suggesting a tax rate of 34% on the transaction. By contrast, now-Ireland's Medtronic ($MDT) paid a 5% tax rate to bring $9.8 billion to the U.S. thanks to corporate inversion.
Regardless, the $2.9 billion in post-tax remitted earnings and $4 billion of low-tax intercompany loans give the company $6.9 billion of cash that's easily accessible outside the U.S. "When combined with US cash flows and netting out debt repayments, dividends, and already modeled buybacks, the company will have $4.7bn in cash it can freely access for value creating activities over the next few years," Denhoy wrote.
Zimmer's been a reluctant dealmaker since the Biomet buy, though it recently made a small move, acquiring Ortho Transmission to get its hands on technology for anchoring artificial limbs that restore mobility among amputees.
The technology will complement Zimmer's work on transcutaneous (across the skin) limb attachment conducted in collaboration with the U.S. Department of Defense, the company said.
And the Defense Logistics Agency just awarded Zimmer a $380 million, fixed-price contract to deliver various orthopedic devices to the Army, Navy, Air Force, Marine Corps and federal civilian agencies through 2021.
Read more on
TokenTalk
? @TokenTalkDD
8m8 minutes ago
Love the tweet and the excitement. Meetings were productive and it was good to close our first project. The beast is out of the cage! Q1 2018 is going to be jam-packed.
Boston,thanks for that post,It was properly my falt on the 10 mil shares being talked about,I was thinking of some thing posted a couple of months ago about 10 mil shares being issued or some thing,so maybe I was reading it wrong,but I quess by your post were good to a billion shares.Im quessing were in for a big year here no matter what happens the company is way,way under valued.And I think we will have our answers real soon HAPPY NEW YEARS to you boston
JayDan, I tried to go back and find where they said they increased the authorized shares,but I couldnt find it,I think it was like by 10 million shares.but it came close enuff for a share for share BO after $AMDA did its reverse split
I agree jayDan,that would put us in line for a share for share trade,1 zimmer share for 1 $AMDA share.I would think that zimmer would want to move on this pretty fast before some one else trys to jump in.If $AMDA were to wait another year I think they could be worth well over a billion,thats why I think zimmer will BO soon.Just think it could only going to cost zimmer about 5 million shares and no cash.zimmer trades about 1.9 million shares a day so this would not effect there share holders at all.win ,win for zimmer,I think they already have the shares set aside in Authorised shares.I beleave they have 10 million shares authorized ( if they were in good mood,they could give us 2 zimmer shares for each $AMDA share I wouldnt complain lol) what ever plays out I think will be real soon and some people will be making some big money glty
zimmers 10day average volume is 1.9 million,so adding 5 million shares to there float of about 200 million will not effect zimmers share price at all and zimmer share holders would be vary happy with what there getting and how much they will add to there earnings
I agree hondobud,so if zimmer were to buy us out that would put us at one share of zimmer for one share $AMDA,maybe even a little more zimmer share
hondobud,dont forget the $200 million in tax credits,that is worth $40.00 a share by its self
$MVES wedman,I think we can get the price a lot higher before someone like nexflix comes in and buys us out,we are just getting started here and have alot going on,we should be able to get to .20 or .30 onces people start seeing are revenues increase quarter over quarter,when movie RAINBOW comes out that could add alot to are revenue stream along with the hugh library of films we are building,Things are looking great here
$MVES looking good CAYO,next couple of quarters should start picking up alot,just got to let our aquisitions to start kicking in and start making our money.after holidays things could really start moving glty
Amedica (NASDAQ: AMDA) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its peers? We will compare Amedica to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.
Earnings and Valuation
Get Amedica alerts:
This table compares Amedica and its peers gross revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio
Amedica $15.23 million -$16.59 million N/A
Amedica Competitors $1.67 billion $207.58 million 58.59
Amedica’s peers have higher revenue and earnings than Amedica.
Volatility and Risk
Amedica has a beta of -2.08, meaning that its stock price is 308% less volatile than the S&P 500. Comparatively, Amedica’s peers have a beta of 0.21, meaning that their average stock price is 79% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Amedica and its peers, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Amedica Competitors 112 734 1028 10 2.50
Amedica presently has a consensus price target of $60.00, indicating a potential upside of 1,954.79%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.88%. Given Amedica’s higher probable upside, equities research analysts plainly believe Amedica is more favorable than its peers.
Institutional & Insider Ownership
63.6% of Amedica shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 0.1% of Amedica shares are held by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Amedica and its peers’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets
Amedica -87.49% -77.71% -45.50%
Amedica Competitors -101.23% -92.70% -30.32%
Summary
Amedica peers beat Amedica on 8 of the 12 factors compared.
About Amedica
Amedica logoAmedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Home
Get Email Updates
About
Disclaimer
Contact
Privacy Policy
American Banking News
Business News
U.S. News
World News
Stock Ratings
Corporate Earnings
Dividends
Research
Head to Head Comparison: Amedica (AMDA) vs. Its Peers
December 12th, 2017 • 0 comments • Filed Under • by ABMN Staff
inShare
Amedica (NASDAQ: AMDA) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Amedica to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Institutional and Insider Ownership
Get Amedica alerts:
63.6% of Amedica shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 0.1% of Amedica shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Amedica has a beta of -2.08, meaning that its share price is 308% less volatile than the S&P 500. Comparatively, Amedica’s rivals have a beta of 0.47, meaning that their average share price is 53% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Amedica and its rivals, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Amedica Competitors 111 732 1028 10 2.50
Amedica presently has a consensus target price of $60.00, suggesting a potential upside of 1,954.79%. As a group, “Medical Devices & Implants” companies have a potential upside of 33.46%. Given Amedica’s higher probable upside, analysts clearly believe Amedica is more favorable than its rivals.
Profitability
This table compares Amedica and its rivals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets
Amedica -87.49% -77.71% -45.50%
Amedica Competitors -101.23% -92.70% -30.32%
Earnings and Valuation
This table compares Amedica and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio
Amedica $15.23 million -$16.59 million -0.72
Amedica Competitors $1.67 billion $207.58 million 79.46
Amedica’s rivals have higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Amedica rivals beat Amedica on 8 of the 12 factors compared.
Amedica Company Profile
Amedica logoAmedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
DNA Brands Inc $DNAX? @dnabrandsinc
1m1 minute ago
Another productive day in Pune India...official PR Update soon......$DNAX #DNAX #ICO #cryptocurrency #plantomorrowtoday #BTC #LTC #ETH #bitcoin #Tokentalk @TokenTalkDD
Wow chris20, 109 board marks,with cayo holding a nice chunk and a few of us others holding big chunks,it wont take much to lock this up tight.with just one nice earnings report we will run this to copper and silver fast,hold your shares tight
$MVES love the volume today,time to start moving up,a little news and we can start to run.next couple of quarters should start showing revenues.we should be good once aquisitions we made start kicking in revenues.holding all shares for long run
CAYO, your getting a good stash there,I will keep adding,The next couple of quarters should start showing increasing revenues GLTY $MVES
Reuters Business?Verified account @ReutersBiz
6m6 minutes ago
Former hedge fund manager Mike Novogratz says mainstream institutional investors will adopt #bitcoin: http://reut.rs/2yZ2xFe #ReutersSummit @Reuters_Summits
sprv picking up speed every day,it will break out
# symbol next to AMDA in my account this morning so quess we get the split today
No hondobud,Im saying either 1 $4 AMDA share for 1 $111.00 ZBH share or maybe even 1 $4 AMDA share for 2 $111.00 share of ZBH.AMDA would have less than 5 mil shares if we do a RS 1for12.With a couple approvals hopefully in the works.AMDA is worth alot of money to ZBH.AND for ZBH to put out 5 or 10 mil shares to take over AMDA it would be nothing to them,but alot to gain
If the 1 for 12 RS is true,this could be setting us up for a BO or merger with zimmer,with a 1 for 1 or 2 for 1 zimmer share for each AMDA share.This would only cost zimmer about 5 to 10 mil shares depending on amda actual share structure.I think it would be closure to 1 for 1 other wise the would have done only a 1 for 6 reverse split.I think some one here said zimmer has already added 10 mil shares to there authorized shares.I think zimmer would try to keep out a bidding war.But $AMDA becomes a easy target with only about 5 mil shares or less.Time will tell,but it does keep us quessing whats going on
ok thanks sweeps